Fig. 5

KRas is essential for the pro-bone metastasis role of MAZ in vivo. a Representative BLIs signal of bone metastasis of a mouse from the indicated groups of mice at 12 mins and 8 weeks respectively. b Representative radiographic images of bone metastases in the indicated mice (arrows indicate osteolytic lesions). c Representative H&E-stained sections of tibias from the indicated mouse. d The sum of bone metastasis score for each mouse in tumor-bearing mice inoculated with MAZ-overexpression (n = 10), MAZ-overexpression and KRas-silencing (n = 10), and MAZ-overexpression and HRas-silencing (n = 10) cells. *P < 0.05. e Quantification of the BLI signaling in MAZ-overexpression, MAZ-overexpression, and KRas-silencing, and MAZ-overexpression and HRas-silencing groups at 25, 35, 45, 55 and 65 days respectively. *P < 0.05. T-test was not performed on days 55 and 65 owing to the death of a large number of mice. f Kaplan-Meyer analysis of mouse survival in the MAZ-overexpression, MAZ-overexpression, and KRas-silencing, and MAZ-overexpression and HRas-silencing groups (Gehan-Breslow-Wilcoxon Test).(G) Kaplan-Meyer analysis of mouse bone metastasis-free survival in the MAZ-overexpression, MAZ-overexpression, and KRas-silencing, and MAZ-overexpression and HRas-silencing groups (Gehan-Breslow-Wilcoxon Test)